SEC Tracker
Get the app
ONC · XBRL financial data

BeOne Medicines financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (ONC's year ends in late December)

In millions of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue from contracts with customers3091,1761,4162,4593,8105,343
Cost of goods and services sold71165286———
Gross profit—1,0111,1292,0793,2164,674
Research and development1,2951,4591,6411,7791,9532,146
Selling, general and administrative6009901,2781,5051,8312,081
Operating income (loss)(1,658)(1,439)(1,790)(1,208)(568)447
Interest income———787071
Interest expense18292242258
Other income (expense)3716(224)308(13)(43)
Income tax expense (benefit)(18)(25)4356112130
Net income (loss)(1,597)(1,413)(2,004)(882)(645)287
Earnings per share, basic USD per share(1.50)(1.17)(1.49)(0.65)(0.47)0.20
Earnings per share, diluted USD per share(1.50)(1.17)(1.49)(0.65)(0.47)0.19
Weighted average shares, basic millions of shares1,0851,2061,3411,3571,3691,418
Weighted average shares, diluted millions of shares1,0851,2061,3411,3571,3691,475

Balance sheet

CSV

Fiscal years (ONC's year ends in late December)

In millions of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents1,3824,3763,8703,1722,6274,548
Short-term investments3,2692,2426653——
Marketable securities3,2692,242————
Accounts receivable60483173358676865
Inventory89243282416495608
Prepaid and other current assets160270217243193213
Total current assets4,9617,6145,2074,2033,9926,234
Property and equipment, net3585888461,3241,5781,642
Right-of-use asset9111711095139148
Goodwill000———
Total assets5,6018,6466,3795,8055,9218,189
Accounts payable232262295315405479
Accrued liabilities3465584676948041,109
Current portion of long-term debt33542832968885257
Total current liabilities1,0751,6001,4691,8102,2151,829
Long-term debt184202209198166962
Lease liability, non-current294335224453
Total liabilities1,7322,4031,9962,2682,5893,827
Accumulated deficit(3,553)(4,966)(7,080)(7,962)(8,607)(8,320)
Total stockholders' equity3,8696,2434,3833,5373,3324,361
Total liabilities and equity5,6018,6466,3795,8055,9218,189
Common shares outstanding (cover page) millions of shares1,1911,3351,3561,3601,3871,442

Cash flows

CSV

Fiscal years (ONC's year ends in late December)

In millions of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(1,597)(1,413)(2,004)(882)(645)287
Stock-based compensation183241303368442511
Depreciation and amortization32466688172142
Net cash from operating activities(1,283)(1,299)(1,497)(1,157)(141)1,128
Purchases of property and equipment118263325562493186
Net cash from investing activities(3,168)6411,07760(548)(276)
Proceeds from issuing common stock4,2325000——
Repayments of long-term debt13200142836
Net cash from financing activities5,2033,637(19)4161931,059
Net change in cash7692,993(508)(689)(547)1,971

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
BeOne Medicines5,0981,705463*1.5B— 10-QJun 30, 2026
Teva Pharmaceutical Industries4,0854,3952411.2B— 10-QSep 30, 2026
Biogen1,3042,804641*147.8M— 10-QSep 30, 2026
United Therapeutics1,189833not reported42.6M— 10-QSep 30, 2026
INSMED397524(36)*219.4M— 10-QSep 30, 2026
Roivant Sciences1,2481.4(271)722.3M14.2 quarters 10-QJun 30, 2026
Neurocrine Biosciences6421,123395*101.2M— 10-QSep 30, 2026
Exelixis305659280*244.0M— 10-QOct 2, 2026
BIO-TECHNE265321*95*156.8M— 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.